Sirnaomics, Inc.
RNAi therapeutics and mRNA vaccines and therapeutics for oncology and other indications
- Sector
- Biotech
- Headquarters
- GAITHERSBURG, MD
- Latest Form D
- $89M, Dec 2020
- Total capital
- $132M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $132M
- 5 Form D · last Dec 2020
- 71 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 33 pending · first 2021
- Rank in peer group#179 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$89M
- Private capital raisedForm D · SEC · 4th filing$7M
- Private capital raisedForm D · SEC · 3rd filing$11M
- Private capital raisedForm D · SEC · 2nd filing$25M
- Offering registeredForm D · SEC · 1st filing$20M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#179 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Da V LiuDirectorNamed in SEC Form D filings
- George JiExecutive OfficerNamed in SEC Form D filings
- Huang V Mingcong (Cooper)DirectorNamed in SEC Form D filings
- Jianjun (George) Ji, MBAExecutive Officer, DirectorNamed in SEC Form D filings
- Michael MolyneauxExecutive Officer, DirectorNamed in SEC Form D filings
- Michael V Molyneaux, MD, MBAExecutive Officer, DirectorNamed in SEC Form D filings
Show all 16 people
- Mike GhiasDirectorNamed in SEC Form D filings
- Mike M Ghias, MBADirectorNamed in SEC Form D filings
- Mongcong (Cooper) V HuangDirectorNamed in SEC Form D filings
- Patrick Y Lu, PhDExecutive Officer, DirectorNamed in SEC Form D filings
- Ping LauDirectorNamed in SEC Form D filings
- Ping Y Lau, MBADirectorNamed in SEC Form D filings
- Rong V Lu, MBADirectorNamed in SEC Form D filings
- Xiaochang DaiDirectorNamed in SEC Form D filings
- Xiaochang V Dai, PhDDirectorNamed in SEC Form D filings
- Yang (Patrick) Lu, PhDExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 40- PendingCHK1-TARGETING Sirnas Chemically Modified With GemcitabineUSPTOApplication 19098292
- PendingProducts And CompositionsUSPTOApplication 19142520
- GrantedOligonucleotides With Nucleoside AnalogsUSPTOUS 12,685,775
Show all 40 patent records
- CHK1-TARGETING Sirnas Chemically Modified With GemcitabineSep 10, 2026 · Application 19098292Pending
- Products And CompositionsJul 30, 2026 · Application 19142520Pending
- Oligonucleotides With Nucleoside AnalogsJul 21, 2026 · US 12,685,775Granted
- An siRNA compound that inhibits expression of APOC3Apr 28, 2026 · US 12,612,626Granted
- An siRNA compound that inhibits complement factor B (CFB).Apr 14, 2026 · US 12,600,967Granted
- Products And CompositionsApr 2, 2026 · Application 19082089Pending
- Products And CompositionsOct 9, 2025 · Application 18982618Pending
- Products And CompositionsOct 9, 2025 · Application 18977340Pending
- Products And CompositionsAug 7, 2025 · Application 18974081Pending
- Oligomeric compound for inhibiting expression of Factor XIAug 5, 2025 · US 12,378,552Granted
- COMPOSITIONS AND METHODS FOR TREATMENT OF CANCERS USING MODIFIED siRNA-GEM AGENTSJan 23, 2025 · Application 18909519Pending
- Peptide Docking Vehicle for Targeted Nucleic Acid DeliveryAug 6, 2024 · US 12,054,714Granted
- COMPOSITION AND METHODS OF RNAi PROPHYLACTICS AND THERAPEUTICS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY INFECTION CAUSED BY 2019 NOVEL CORONAVIRUS (2019-nCoV)Jun 11, 2024 · US 12,006,500Granted
- Compositions And Methods For Inhibiting Expression Of PCSK9May 30, 2024 · Application 18179410Pending
- NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASESMay 16, 2024 · Application 18126145Pending
- COMBINATION siRNA AND PEPTIDE DOCKING VEHICLE (PDoV) COMPOSITIONS AND METHODS OF THEIR USE FOR IMPROVED REGULATION AND FUNCTIONALITYApr 4, 2024 · Application 18365052Pending
- METHODS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF 2019-nCoV USING siRNAs AGAINST ORF1AB and N-ProteinApr 4, 2024 · Application 18111335Pending
- Targeted Nucleic Acid Therapy For Hepatitis BDec 7, 2023 · Application 18179123Pending
- Methods For Inducing Adipose Tissue Remodeling Using Rnai TherapeuticsNov 16, 2023 · Application 18355280Pending
- Compositions And Methods For Treatment Of Skin CancersNov 9, 2023 · Application 18355637Pending
- COMPOSITION AND USE OF siRNAs AGAINST VEGFR2 AND TGF-BETA1 IN COMBINATION THERAPY FOR CANCEROct 12, 2023 · Application 18179573Pending
- METHODS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF 2019-nCoV USING siRNAs AGAINST TGFB1 AND COX2Aug 17, 2023 · Application 18111309Pending
- Products And CompositionsAug 17, 2023 · Application 18170971Pending
- siRNA-Copolymer Compositions And Methods Of Use For Treatment Of Liver CancerAug 10, 2023 · Application 17867260Pending
- Nanoparticle Pharmaceutical Compositions With Reduced Nanoparticle Size And Improved Polydispersity IndexJul 27, 2023 · Application 17935022Pending
- Methods For Preparing Nanoparticle Compositions Containing Histidine-lysine CopolymersApr 20, 2023 · Application 17951842Pending
- Nanoparticle Formulations Formed From Histidine-lysine CopolymersMar 30, 2023 · Application 17935014Pending
- Products And CompositionsMar 23, 2023 · Application 17843657Pending
- METHODS OF CANCER TREATMENT BY DELIVERY OF siRNAs AGAINST NSD3Dec 29, 2022 · Application 17697717Pending
- Tumor-Targeting Polypeptide Nanoparticle Delivery System for Nucleic Acid TherapeuticsOct 20, 2022 · Application 17713037Pending
- Combinations Of Sirnas With Sirnas Against SULF2 Or GPC3 For Use In Treating CancerOct 20, 2022 · Application 17711975Pending
- METHODS OF CANCER TREATMENT BY DELIVERY OF siRNAs AGAINST BCLXL AND MCL1 USING A POLYPEPTIDE NANOPARTICLESep 15, 2022 · Application 17694224Pending
- CO-DELIVERY OF TGF-B siRNA AND PDL1 siRNA TO TREAT CANCERSep 8, 2022 · Application 17694316Pending
- siRNA/Nanoparticle Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral InfectionMay 12, 2022 · Application 17373361Pending
- Targeted Delivery of Therapeutic MoleculesFeb 24, 2022 · Application 17361164Pending
- Multi-Targeting Nucleic Acid Constructs Composed Of Multiple Oligonucleotides That Modulate Gene Expression Through Complimentary Interactions With TargetsDec 2, 2021 · Application 17215964Pending
- MINIATURIZED HAIRPIN RNAi TRIGGERS (mxRNA) AND METHODS OF USES THEREOFOct 28, 2021 · Application 17187309Pending
- SILENCING TGF-BETA 1 and COX2 USING siRNAs DELIVERED in a POLYPEPTIDE NANOPARTICLE ALONE and in COMBINATION with IMMUNE CHECKPOINT INHIBITORS to TREAT CANCEROct 21, 2021 · Application 17361109Pending
- sirna/Nanoparticle Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral InfectionJul 13, 2021 · US 11,058,779Granted
- Composition and Methods of Controllable Co-Coupling Polypeptide Nanoparticle Delivery System for Nucleic Acid TherapeuticsJun 3, 2021 · Application 17103386Pending
Related companies, and why
- Nuvalent, Inc.Similar federal contract value in Biotech · null in contracts
- Electra TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Caribou BiosciencesSimilar federal contract value in Biotech · null in contracts
- Terrestrial Bio, Inc.Similar federal contract value in Biotech · null in contracts
- iTeos TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Star TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .